I think the drug will get approval. That's not my concern. The concern is the stock is already priced for approval. How much revenue could they generate on this drug. Their pipeline is far from approval. I don't understand how these stocks get to these prices with no sales. I have pharma stocks that are generating millions in revenue and they are half the price of this company.
I don't know anything about this company other than what I saw on CNBC and some research I did today.
I certainly hope they can get approval. It sounds like the drug is working and the is a need for it. I am debating on taking a stake in the company. But my concern is its already priced high (over $18) considering they don't any sales & their pipeline drugs are far from approved. And if DMD is approved how much revenue can it generate. Enough to substantiate $18 per share?